Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of the Association of Iodobenzylguanidine Meta-I131 (I131 MIBG) and Topotecan in the Treatment of Refractory or Relapsed Metastatic Neuroblastoma

NCT00960739 is registered in ClinicalTrials.gov with Centre Oscar Lambret as lead sponsor.

NCT NCT00960739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00960739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of the Association of Iodobenzylguanidine Meta-I131 (I131 MIBG) and Topotecan in the Treatment of Refractory or Relapsed Metastatic Neuroblastoma
Lead sponsor
Centre Oscar Lambret
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2008
Completion date
July 31, 2016
Enrollment
30 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma